US Stocks

Artelo Biosciences, Inc.

Artelo Biosciences is a clinical stage biopharmaceutical company that is primarily focused on developing and commercializing treatments for the modulation of the endocannabinoid system. Their pipeline of product candidates includes a synthetic G protein-coupled receptor agonist, a synthetic cannabidiol cocrystal, and a fatty acid binding protein 5 inhibitor that is used for treating prostate and breast cancer and PTSD. Artelo Biosciences also collaborates with Trinity College Dublin to research ART27.13 for cancer cachexia treatment.